共 50 条
- [1] Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast CancerMOLECULAR CANCER THERAPEUTICS, 2018, 17 (05) : 908 - 920Michaloglou, ChrysiisCrafter, ClaireSiersbaek, RasmusDelpuech, OonaCurwen, Jon O.Carnevalli, Larissa S.Staniszewska, Anna D.Polanska, Urszula M.Cheraghchi-Bashi, AzadehLawson, MandyChernukhin, IgorMcEwen, RobertCarroll, Jason S.Cosulich, Sabina C.
- [2] Radiosensitization of Estrogen Receptor Positive Breast Cancers with Short-Term CDK4/6 InhibitionINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : S57 - S58Pesch, A.Hirsh, N.Chandler, B.Michmerhuizen, A. R.Wilder-Romans, K.Liu, M.Ritter, C.Androsiglio, M.Gersch, C.Larios, J.Pierce, L. J.Rae, J.Speers, C.
- [3] Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast CancersCLINICAL CANCER RESEARCH, 2020, 26 (24) : 6568 - 6580Pesch, Andrea M.Hirsh, Nicole H.Chandler, Benjamin C.Michmerhuizen, Anna R.Ritter, Cassandra L.Androsiglio, Marlie P.Wilder-Romans, KariLiu, MeilanGersch, Christina L.Larios, Jose M.Pierce, Lori J.Rae, James M.Speers, Corey W.
- [4] Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast CancerCANCER RESEARCH, 2016, 76 (08) : 2301 - 2313Herrera-Abreu, Maria TeresaPalafox, MartaAsghar, UzmaRivas, Martin A.Cutts, Rosalind J.Garcia-Murillas, IsaacPearson, AlexGuzman, MartaRodriguez, OlgaGrueso, JuditBellet, MeritxellCortes, JavierElliott, RichardPancholi, SunilBaselga, JoseDowsett, MitchMartin, Lesley-AnnTurner, Nicholas C.Serra, Violeta
- [5] Mdm2 inhibition synergises with endocrine therapy or cdk4/6 inhibition for the treatment of estrogen receptor-positive breast cancerCANCER RESEARCH, 2021, 81 (04)Portman, NeilMilioli, HeloisaAlexandrou, SarahCoulson, RhiannonYong, AlizaFernandez, KristineChia, KeeMingHalilovic, EnsarSegara, DavendraParker, AndrewHaupt, SueHaupt, YgalTilley, WayneSwarbrick, AlexCaldon, LizLim, Elgene
- [6] CDK4/6 inhibition in HER2-positive breast cancer CommentLANCET ONCOLOGY, 2020, 21 (06): : 734 - 735Battisti, Nicolo Matteo LucaRing, Alistair
- [7] STAT3 as a therapeutic target in estrogen receptor positive breast cancer patients refractory to CDK4/6 inhibitionCANCER RESEARCH, 2020, 80 (04)Kettner, Nicole M.Bui, TuyenHa, Min JinEckols, T. KrisTweardy, David J.Meric-Bernstam, FundaHunt, Kelly K.Tripathy, DebuKeyomarsi, Khandan
- [8] CDK4/6 Inhibition Suppresses Myeloma Cell Growth and Viability via Perturbation of E2F Proliferative ProgramCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E126 - E127Chakraborty, ChandradityaDerebail, SanikaSamur, MehmetLin, CharlesAnderson, Kenneth C.Fulciniti, MariateresaMunshi, Nikhil
- [9] Mechanistic exploration of combined CDK4/6 and ER inhibition in ER-positive breast cancerCANCER RESEARCH, 2014, 74 (19)Lee, Nathan V.Yuan, JingEisele, KoleenCao, Joan Q.Painter, Cory L.Chionis, JohnLiu, ChaotingShields, David J.Kan, Julie L. C.Arndt, KimVanArsdale, Todd
- [10] Combined Inhibition of mTOR and BTK Signaling Is Required for Optimal Long Term Growth Inhibition in DLBCL ModelsBLOOD, 2017, 130Brugger, WolframHattersley, MaureenBussey, AlexandraReimer, CorinneTron, Adriana E.Staniszewska, AnnaDelpuech, OonaCarnevalli, LarissaKrejsa, Cecile M.Mayo, MicheleNeveras, LynneSan Martin, MaryannRideout, AblaProia, TheresaWillis, BrandonPease, J. ElizabethHamdy, AhmedCosulich, Sabina C.